<DOC>
	<DOCNO>NCT01999192</DOCNO>
	<brief_summary>The purpose study determine efficacy safety three different Tregalizumab dose combination Methotrexate ( MTX ) subject active rheumatoid arthritis inadequate response MTX alone . The overall study duration 24 week follow 24 week extension phase .</brief_summary>
	<brief_title>Study Investigate Safety Efficacy Tregalizumab Subjects ( MTX-IR ) With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>The plan clinical study 986 ( TREAT 2b ) 24-week study patient Active rheumatoid arthritis ( RA ) inadequate response Methotrexate ( MTX ) alone . The main phase study follow 24-week extension phase subject meet respective entry criterion . Patients randomize one three different Active treatment group Placebo .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Subject demonstrate active RA accord 1987 American College Rheumatology ( ACR ) 2010 ACR/European League Against Rheumatism ( EULAR ) classification criterion RA functional class IIII ≥6 month . 2 . Subject receive oral parenteral MTX treatment ≥12 week ( overall ) , unchanged mode application stable MTX dose ≥15 mg per week ( ≥12.5 mg per week case MTX intolerance ) , high locally approve dose RA , ≥8 week prior baseline . The dose MTX expect remain stable throughout study may adjust safety reason . If applicable , dose folic acid must unchanged ≥8 week prior baseline . 3 . Subject meet follow two criterion screen baseline : − At least 6 swollen joint 28joint assessment . − At least 6 tender joint 28joint assessment . 4 . Subject erythrocyte sedimentation rate ( ESR ) Creactive protein ( CRP ) upper limit normal ( ULN ) screening . These test may repeat screen period discretion investigator . 5 . Subject ≥18 ≤75 year age . 6 . Subject body mass index ≥18 ≤35 kg/m² . 7 . Subject receive treatment corticosteroid ≤10 mg prednisone equivalent , stable least 4 week prior baseline study , applicable . 8 . Subject receive treatment nonsteroidal antiinflammatory drug ( NSAIDs ) , stable least 2 week prior baseline study , applicable . 9 . Female subject childbearing potential : negative serum pregnancy test screen negative urine pregnancy test baseline . 10 . Subject judge good general health determine investigator base upon result medical history , laboratory profile , physical examination , chest Xray ( within 3 month screen date acceptable ) , 12−lead electrocardiogram ( ECG ) . 11 . Subject cluster differentiation 4 ( CD4 ) cell count &gt; 400/µl screening . 1 . Subject previous exposure systemic biologic therapy ( e.g. , etanercept , adalimumab , rituximab , abatacept , tocilizumab ) , Janus kinase ( JAK ) spleen tyrosine kinase ( SYK ) inhibitor , Tregalizumab . Previous treatment antiTNF agent allow , follow criterion apply : − treatment stop reason lack efficacy adverse event ( AEs ) − treatment stop least 12 week five halflives compound prior baseline ( whichever longer ) , − treatment period exceed 6 week . 2 . Subject receive treatment conventional diseasemodifying antirheumatic drug ( DMARDs ) apart MTX 12 week prior baseline , DMARD leflunomide 24 week prior baseline ( except specific leflunomide washout procedure complete , follow applicable guideline ) . 3 . Subject treat intraarticular parenteral administration corticosteroid 4 week prior baseline . Inhaled corticosteroid stable medical condition allow . 4 . Subject undergone joint surgery 12 week prior baseline ( joint assess within study ) undergone major surgery ( e.g. , abdominal surgery ) 8 week prior baseline . 5 . Subject history acute inflammatory joint disease origin RA subject rheumatic disease RA ( e.g. , mixed connective tissue disease , seronegative spondylarthropathy , psoriatic arthritis , Reiter 's syndrome , fibromyalgia , systemic lupus erythematosus arthritis onset prior age 17 year ) . However , subject may secondary Sjögren 's syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>inadequate response MTX</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>rheumatoid Arthritis</keyword>
	<keyword>Phase 2b</keyword>
</DOC>